Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bausch & Lomb Incorporated
The main purpose of this prospective study is to demonstrate the therapeutic equivalence of topical brinzolamide dosed three times daily compared with AzoptTM (brinzolamide ophthalmic suspension 1%) dosed three times daily in IOP reduction in patients with POAG or OH.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male and females 18 years of age or older,
diagnosed with primary open-angle glaucoma or ocular hypertension.
You may not be if
Patients with any form of glaucoma (such as secondary, congenital, juvenile or normal tension glaucoma, angle closure glaucoma) in either eye other than primary open-angle glaucoma,
